Base de dados : MEDLINE
Pesquisa : D03.383.742.698.875.404.850 [Categoria DeCS]
Referências encontradas : 5248 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 525 ir para página                         

  1 / 5248 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374719
[Au] Autor:Fujii T; Horiguchi J; Yanagita Y; Koibuchi Y; Ikeda F; Uchida N; Kimura M; GUNMA BREAST CLINICAL CONFERENCE STUDY GROUP (GBCCSG)
[Ad] Endereço:Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan ftakaaki@gunma-u.ac.jp.
[Ti] Título:Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).
[So] Source:Anticancer Res;38(2):905-909, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: Treatment strategies for patients with human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC) have significantly progressed. The use of trastuzumab, a monoclonal antibody targeting the HER2 (human epidermal growth factor 2) protein, in combination with chemotherapy improves survival in patients with HER2-positive breast cancer. S-1, an oral combination of fluorouracil derivatives, is widely used in Japan and is more convenient than intravenous drugs. However, little is known about the combination of S-1 and trastuzumab in patients with HER2-positive MBC. PATIENTS AND METHODS: We conducted a single-arm, open-label, multicenter prospective phase II study to evaluate the efficacy of an S-1 plus trastuzumab regimen for HER2-positive MBC. S-1 was administered orally [80-120 mg, based on body surface area (BSA)] twice a day for 14 consecutive days in a 3-week cycle. Patients with BSA of <1.25 m received a total of 80 mg of S-1, those with BSA ≥1.5 m received 120 mg, and the remaining received 100 mg daily in two divided doses. Trastuzumab was administered intravenously at 8 mg/kg on day 1 of the first cycle and at 6 mg/kg on day 1 of subsequent cycles, i.e., every 3 weeks. RESULTS: Between December 2008 and March 2013, 10 patients were enrolled and received a median of 17 (range=3-76) cycles of treatment. Overall response and clinical benefit rates were 60.0% and 90.0%, respectively. Progression-free survival was 15.8 (95% confidence interval=9.4-29.6) months and overall survival was 45.5 (95% confidence interval=37.1-62.2) months. Grade 3/4 adverse events included were neutropenia and hyperglycemia in one patient each (10.0%). There was no clinically significant cardiotoxicity. CONCLUSION: The combination of S-1 and trastuzumab was tolerable and had excellent efficacy with good response and disease control in this study. S-1 plus anti-HER2 therapy is a feasible treatment option for HER2-positive MBC.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias da Mama/tratamento farmacológico
Receptor ErbB-2/metabolismo
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Neoplasias da Mama/enzimologia
Neoplasias da Mama/patologia
Combinação de Medicamentos
Feminino
Seres Humanos
Meia-Idade
Estadiamento de Neoplasias
Ácido Oxônico/administração & dosagem
Estudos Prospectivos
Tegafur/administração & dosagem
Trastuzumab/administração & dosagem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Drug Combinations); 150863-82-4 (S 1 (combination)); 1548R74NSZ (Tegafur); 5VT6420TIG (Oxonic Acid); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor, ErbB-2); P188ANX8CK (Trastuzumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  2 / 5248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390514
[Au] Autor:Wei J; Dong X; Du F; Tang S; Wei H
[Ad] Endereço:Department of Medical Oncology.
[Ti] Título:Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancer: A case report.
[So] Source:Medicine (Baltimore);96(51):e9338, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Pancreatic cancer is common in people older than 40 years, and the incidence peaks at the age of 70 years and older. Chemoradiotherapy has been generally considered a high-risk procedure in elderly patients with local recurrent pancreatic cancer. Gamma knife stereotactic radiosurgery has the advantage in protecting the surrounding tissues, and providing short-term effects. It has been successfully used in patients with brain metastases.The efficacy of GKSRS in other malignancies has barely been studied.S-1 is one of the key drug against metastatic and local advanced pancreatic cancer. The combination of GKSRS and S-1 in local recurrent pancreatic cancer has hardly been reported. PATIENT CONCERNS: We present a rare case of a 76-year-old man with pancreatic cancer. He complained of recurrent abdominal pain and chronic pain in the right shoulder for more than 3 years. DIAGNOSES: After several examinations, the diagnosis was carcinoma of the pancreas. INTERVENTIONS: A resection of the pancreatic neoplasm was performed on June 21, 2011; he did not receive adjuvant chemotherapy. In April 2014, postoperative recurrence was confirmed in the head of the pancreas. The patient received gamma knife stereotactic radiosurgery (GKSRS) combined with S-1 treatment. OUTCOMES: The patient showed complete response after 2 months. He has achieved an overall survival of 76 months with a very good performance status. LESSONS: GKSRS applied to other malignancies has rarely been reported. S-1 is the key drug for adjuvant chemotherapy in resected pancreatic cancer. There are a few studies on this combination in local recurrent pancreatic cancer. GKSRS combined with S-1 seems to be a good option in improving efficacy and prolonging life in elderly patients with locally recurrent pancreatic cancer.
[Mh] Termos MeSH primário: Adenocarcinoma/cirurgia
Recidiva Local de Neoplasia/terapia
Ácido Oxônico/uso terapêutico
Neoplasias Pancreáticas/patologia
Neoplasias Pancreáticas/cirurgia
Radiocirurgia/métodos
Tegafur/uso terapêutico
[Mh] Termos MeSH secundário: Adenocarcinoma/patologia
Idoso
Quimioterapia Adjuvante
Combinação de Medicamentos
Seguimentos
Seres Humanos
Masculino
Recidiva Local de Neoplasia/patologia
Neoplasias Pancreáticas/diagnóstico por imagem
Medição de Risco
Fatores de Tempo
Tomografia Computadorizada por Raios X/métodos
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 150863-82-4 (S 1 (combination)); 1548R74NSZ (Tegafur); 5VT6420TIG (Oxonic Acid)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009338


  3 / 5248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29221445
[Au] Autor:Kawamoto Y; Komatsu Y; Yuki S; Sawada K; Muranaka T; Harada K; Nakatsumi H; Fukushima H; Ishiguro A; Dazai M; Hatanaka K; Nakamura M; Iwanaga I; Uebayashi M; Sogabe S; Kobayashi Y; Miyagishima T; Ono K; Sakamoto N; Sakata Y
[Ad] Endereço:Department of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.
[Ti] Título:Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
[So] Source:BMC Cancer;17(1):837, 2017 12 08.
[Is] ISSN:1471-2407
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In Japan, S-1 plus cisplatin (SP) regimen has become a standard therapy for patients with advanced gastric cancer. Moreover, the S-1 plus oxaliplatin regimen is now a standard treatment. Nab-paclitaxel was developed for chemotherapy of gastric cancer in Japanese clinical practice. Nab-paclitaxel, created with albumin-bound paclitaxel particles, has high transferability to tumour tissues and does not cause hypersensitivity reactions because of a different chemical composition compared with docetaxel and paclitaxel. A combination of S-1, nab-paclitaxel and oxaliplatin (which we named 'SNOW regimen') can be a promising triplet therapy for advanced gastric cancer. Although we have to pay attention to chemotherapy-induced neuropathy, we aim to investigate the recommended dose of this regimen in a phase I study. Furthermore, we will investigate its efficacy and toxicity in a phase II study. METHODS: The phase I study is a dose-escalation study using a standard 3 plus 3 design, followed by expansion cohorts. The SNOW regimen involves 28-day cycles with escalated doses of nab-paclitaxel (100-175 mg/m on days 1 and 15) and fixed doses of oxaliplatin (65 mg/ m on days 1 and 15) and S-1 (80 mg/m /day on day 1 to 14). The primary endpoints are assessment of dose limiting toxicities and determination of maximum tolerated dose to investigate the recommended dose in the subsequent phase II study. In the phase II study, the primary endpoint is objective response rate. Secondary endpoints are assessment of safety, progression-free survival, disease control rate, overall survival and time to treatment failure. Adverse events were monitored and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. DISCUSSION: Triplet therapies for advanced gastric cancer patients have been evaluated in clinical trials. The SNOW regimen can be a promising new triplet therapy. TRIAL REGISTRATION: This study is performed at institutes that participate in Hokkaido Gastrointestinal Cancer Study Group (HGCSG) and registered as UMIN000016788 . Registrated 16 March 2015.
[Mh] Termos MeSH primário: Albuminas
Protocolos de Quimioterapia Combinada Antineoplásica
Compostos Organoplatínicos
Ácido Oxônico
Paclitaxel
Neoplasias Gástricas/tratamento farmacológico
Tegafur
[Mh] Termos MeSH secundário: Adulto
Albuminas/administração & dosagem
Albuminas/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Combinação de Medicamentos
Seres Humanos
Compostos Organoplatínicos/administração & dosagem
Compostos Organoplatínicos/uso terapêutico
Ácido Oxônico/administração & dosagem
Ácido Oxônico/uso terapêutico
Paclitaxel/administração & dosagem
Paclitaxel/uso terapêutico
Neoplasias Gástricas/mortalidade
Tegafur/administração & dosagem
Tegafur/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (130-nm albumin-bound paclitaxel); 0 (Albumins); 0 (Drug Combinations); 0 (Organoplatinum Compounds); 04ZR38536J (oxaliplatin); 150863-82-4 (S 1 (combination)); 1548R74NSZ (Tegafur); 5VT6420TIG (Oxonic Acid); P88XT4IS4D (Paclitaxel)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180217
[Lr] Data última revisão:
180217
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171210
[St] Status:MEDLINE
[do] DOI:10.1186/s12885-017-3850-z


  4 / 5248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29226661
[Au] Autor:Kabashima A; Kimura K; Sanefuji K; Maekawa S
[Ti] Título:Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report.
[So] Source:Fukuoka Igaku Zasshi;108(1):8-13, 2017 Jan.
[Is] ISSN:0016-254X
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Although chemotherapy with oral S-1and oxaliplatin (SOX) plus bevacizumab (bev) is safe and feasible for patients with advanced or recurrent colorectal cancer, it is difficult to achieve a complete response (CR) using only chemotherapy. A 67-year-old man underwent endoscopic mucosal resection and additional sigmoidectomy (D2 dissection) for submucosal invasive sigmoid colon cancer. Multiple liver metastases were diagnosed 1.5 years later, and chemotherapy with SOX + bev was initiated. Computed tomography (CT) after the end of the third course revealed reduced liver recurrence. Liver metastases could not be identified using CT after the end of the sixth course. Grade 1peripheral neuropathy was the only side effect of this regimen. Subsequently, the chemotherapy regimen was changed to oral S-1. CT evaluation revealed that there was no recurrence at 6 months after the regimen change.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias do Colo/patologia
Neoplasias Hepáticas/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Bevacizumab/administração & dosagem
Neoplasias do Colo/tratamento farmacológico
Combinação de Medicamentos
Seres Humanos
Neoplasias Hepáticas/secundário
Masculino
Compostos Organoplatínicos/administração & dosagem
Ácido Oxônico/administração & dosagem
Recidiva
Tegafur/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Organoplatinum Compounds); 04ZR38536J (oxaliplatin); 150863-82-4 (S 1 (combination)); 1548R74NSZ (Tegafur); 2S9ZZM9Q9V (Bevacizumab); 5VT6420TIG (Oxonic Acid)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE


  5 / 5248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245275
[Au] Autor:Wen Y; Zhao Z; Miao J; Yang Q; Gui Y; Sun M; Tian H; Jia Q; Liao D; Yang C; Du X
[Ad] Endereço:aDepartment of Oncology, Mianyang Central Hospital, Mian YangbDepartment of Oncology, Affiliated Hospital of North Sichuan Medical College, Nan ChongcDepartment of Oncology, Zigong Fourth People's Hospital, Zi GongdDepartment of Oncology, Ziyang People's Hospital, Zi YangeDepartment of Oncology, Guangyuan First People's Hospital, Guang YuanfDepartment of Oncology, Jiangyou People's HospitalgDepartment of Oncology, Jiangyou Second People's Hospital, Jiang YouhDepartment of Oncology, Jianyang People's Hospital, Jian Yang, Sichuan, People's Republic of China.
[Ti] Título:S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial.
[So] Source:Medicine (Baltimore);96(49):e8998, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Chemotherapy regimens are often a 2-drug regimen in concurrent chemotherapy and radiotherapy for esophageal cancer (EC). However, some retrospective studies have suggested that for patients with EC receiving radiotherapy combined with 2-drug chemotherapy have the severe toxicity. And S-1 alone with the combination of radiotherapy treatment effect is good, and achieved good clinical remission rate. The purpose of this trial is compare the efficacy and toxicity of combining S-1 or S-1 plus cisplatin with radiotherapy for esophageal squamous cell carcinoma. METHODS/DESIGN: The study is a randomized, controlled, multicenter trial, comparing S-1 versus S-1 plus cisplatin concurrent radiotherapy for patients with esophageal squamous cell carcinoma. Eighty-eight patients with unresectable or medically unfit for surgery esophageal squamous cell carcinoma (clinical stage I to III), will randomly assigned to receive four cycles (2 concomitant and 2 postradiotherapy) S-1 or S-1 plus cisplatin along with radiotherapy 60-66 Gy/30 to 33 fractions. The primary outcome is complete response rate of primary tumor which will be measured by endoscopy and computer screen at 3 months after the completion of treatment. Secondary outcomes include survival and toxicity. DISCUSSION: To our knowledge, this study protocol is the first to test the effect between S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma. If the result will be the same effect and fewer side effects and less costly in S-1 plus radiotherapy. It will supply more treatment selection for esophageal squamous cell carcinoma.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/terapia
Quimiorradioterapia/métodos
Cisplatino/uso terapêutico
Neoplasias Esofágicas/terapia
Ácido Oxônico/uso terapêutico
Tegafur/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Cisplatino/administração & dosagem
Combinação de Medicamentos
Feminino
Seres Humanos
Masculino
Meia-Idade
Ácido Oxônico/administração & dosagem
Tegafur/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Drug Combinations); 150863-82-4 (S 1 (combination)); 1548R74NSZ (Tegafur); 5VT6420TIG (Oxonic Acid); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008998


  6 / 5248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29187494
[Au] Autor:Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Sui K; Shimada Y; Iiyama T
[Ad] Endereço:Department of Gastroenterological Surgery at Kochi Health Sciences Center, Kochi, Japan tokabaya@gmail.com.
[Ti] Título:Characterization of Prognostic Factors and the Efficacy of Adjuvant S-1 Chemotherapy in Patients with Post-surgery Extrahepatic Bile Duct Cancer.
[So] Source:Anticancer Res;37(12):7049-7056, 2017 12.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: There is no clear consensus on the type of adjuvant therapy that should be used for patients with extrahepatic bile duct cancer. PATIENTS AND METHODS: Two hundred and seventy-one patients that had undergone surgical resection for extrahepatic bile duct cancer composed the study cohort. Demographics, treatments, and relationships between the potential prognostic factors and survival rates were analyzed. RESULTS: The overall 3-year and 5-year survival rates for post-surgery extrahepatic bile duct cancer patients were 49.0% and 35.4%, respectively. Multivariate analysis revealed that regional lymph node metastasis was an independent negative prognostic factor. We observed a significant correlation between node-positive extrahepatic bile duct cancer and postoperative local recurrence, liver metastasis, peritoneal dissemination, and post-surgery lymph node metastasis. Adjuvant S-1 chemotherapy showed a favorable hazard ratio in patients with lymph node metastases or positive vascular invasion. CONCLUSION: We recommend the use of adjuvant S-1 therapy in patients with lymph node metastases or microvascular invasion.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias dos Ductos Biliares/tratamento farmacológico
Ductos Biliares Extra-Hepáticos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias dos Ductos Biliares/cirurgia
Ductos Biliares Extra-Hepáticos/cirurgia
Quimioterapia Adjuvante
Feminino
Seguimentos
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Análise Multivariada
Recidiva Local de Neoplasia
Ácido Oxônico/administração & dosagem
Prognóstico
Estudos Retrospectivos
Tegafur/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
1548R74NSZ (Tegafur); 5VT6420TIG (Oxonic Acid)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE


  7 / 5248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29061504
[Au] Autor:Das K; Taguri M; Imamura H; Sugimoto N; Nishikawa K; Yoshida K; Tan P; Tsuburaya A
[Ad] Endereço:Cancer and Stem Cell Biology Program, Duke-NUS Medical School, 8 College Rd., Singapore. Electronic address: kaks23@yahoo.com.
[Ti] Título:Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial.
[So] Source:Cancer Lett;412:208-215, 2018 Jan 01.
[Is] ISSN:1872-7980
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Recent gastric cancer clinical trials have aimed to establish the efficacy of combination therapy over monotherapy, however, the role for genomic biomarkers in these trials has remained largely unexplored. Here, using the NanoString expression platform, we analyzed 105 gastric tumors from a randomized phase III Japanese clinical trial (GC0301/TOP002) testing the efficacy of irinotecan plus S-1(IRI-S) versus S-1 therapy. We found that previously established proliferative subtype signatures, were associated with older patients (>65 years) and liver metastasis while mesenchymal subtype signatures were associated with younger patients (≤65 years) and peritoneal metastasis. Genes associated with tumor microenvironment (CD4, CD14, ADAMTS1, CCL5, CXCL12, CCL19), therapeutic implications (DPYD) and oncogenic signaling (Wnt5A, PTRF) were significantly associated with patient age, histology, tumor status, measurable lesions and metastasis. We identified Wnt5A downregulation as a candidate predictor of improved progression free survival (>8 weeks) in S-1 but not in IRI-S treatment. Although statistical significance was not achieved, mesenchymal subtype showed a trend for treatment interaction with IRI-S for efficacy. These findings highlight promising genomic markers that could be useful predictors of chemotherapy efficacy for better prognosis and survival outcome in gastric cancer.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Recidiva Local de Neoplasia/tratamento farmacológico
Neoplasias Gástricas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Camptotecina/administração & dosagem
Camptotecina/análogos & derivados
Combinação de Medicamentos
Feminino
Seres Humanos
Neoplasias Hepáticas/secundário
Masculino
Meia-Idade
Recidiva Local de Neoplasia/genética
Ácido Oxônico/administração & dosagem
Neoplasias Gástricas/genética
Neoplasias Gástricas/mortalidade
Neoplasias Gástricas/patologia
Tegafur/administração & dosagem
Proteína Wnt-5a/genética
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Drug Combinations); 0 (WNT5A protein, human); 0 (Wnt-5a Protein); 150863-82-4 (S 1 (combination)); 1548R74NSZ (Tegafur); 5VT6420TIG (Oxonic Acid); 7673326042 (irinotecan); XT3Z54Z28A (Camptothecin)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171205
[Lr] Data última revisão:
171205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE


  8 / 5248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29040299
[Au] Autor:Cho JH; Lim JY; Cho JY
[Ad] Endereço:Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
[Ti] Título:Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
[So] Source:PLoS One;12(10):e0186362, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AIM: To compare capecitabine and oxaliplatin (XELOX) with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. METHODS: Clinical data from 206 patients who received XELOX or S-1 regimens as adjuvant chemotherapy in stage III gastric cancer were collected. Patients were divided into 2 groups according to regimen; the groups were XELOX (n = 114) and S-1 monotherapy (n = 92). RESULTS: 3-year disease-free survival (DFS) was higher in the S-1 group than in the XELOX group (66.6% vs 59.1%; p = 0.636). 3-year overall survival (OS) was 75.6% in the S-1 group and 69.6% in the XELOX group (p = 0.495). But, the difference was not statistically significant. Especially, for patients with stage IIIC disease, 3-year overall survival was 55.2% in the XELOX group and 39.0% in the S-1 group (hazard ratio, HR 0.50, 95% confidence interval, CI 0.23-1.10; p = 0.075). In multivariate analysis, N stage (HR, 5.639; 95% CI, 1.297-24.522; p = 0.021) and cycle completion as planned (HR, 5.734; 95% CI, 3.007-10.936; p<0.001) were independent predictors of overall survival. CONCLUSION: Adjuvant XELOX and S-1 regimen did not prove anything superior for stage III gastric cancer in this study. But, XELOX had a tendency to be superior to S-1 in stage IIIC gastric cancer after D2 gastrectomy although the difference was not statistically significant. N stage and cycle completion as planned were prognostic factors.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Quimioterapia Adjuvante/métodos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia
Neoplasias Gástricas/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Capecitabina/administração & dosagem
Quimioterapia Adjuvante/efeitos adversos
Intervalo Livre de Doença
Combinação de Medicamentos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/classificação
Feminino
Gastrectomia
Seres Humanos
Masculino
Meia-Idade
Estadiamento de Neoplasias
Compostos Organoplatínicos/administração & dosagem
Ácido Oxônico/administração & dosagem
Neoplasias Gástricas/patologia
Neoplasias Gástricas/cirurgia
Tegafur/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Organoplatinum Compounds); 04ZR38536J (oxaliplatin); 150863-82-4 (S 1 (combination)); 1548R74NSZ (Tegafur); 5VT6420TIG (Oxonic Acid); 6804DJ8Z9U (Capecitabine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171018
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186362


  9 / 5248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28763145
[Au] Autor:Li J; Xu R; Xu J; Denda T; Ikejiri K; Shen L; Toh Y; Shimada K; Kato T; Sakai K; Yamamoto M; Mishima H; Wang J; Baba H
[Ad] Endereço:Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
[Ti] Título:Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
[So] Source:Cancer Sci;108(10):2045-2051, 2017 Oct.
[Is] ISSN:1349-7006
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A phase II study of S-1 plus leucovorin (LV) given in a 4-week schedule (2 weeks' administration followed by 2 weeks' rest) for patients with untreated metastatic colorectal cancer (mCRC) showed that the combination was effective, but grade 3 toxicities (diarrhea, stomatitis and anorexia) occurred at a relatively high rate. In this phase II study, we evaluated the efficacy and safety of a 2-week schedule of S-1 plus LV. Patients with mCRC received oral S-1 (40-60 mg) and LV (25 mg) twice daily for 1 week, followed by 1 week's rest. Treatment was repeated until disease progression or unacceptable toxicity. The primary endpoint was response rate. The pharmacokinetics of S-1 and LV in Chinese patients were evaluated on day 1 of the first cycle. Seventy-three patients were enrolled in Japan and China. Of 71 eligible patients, the response rate was 53.5%, and the disease control rate was 83.1%. Median progression-free survival and median overall survival were 6.5 and 24.3 months, respectively. The incidences of grade 3 toxicities were diarrhea 8.3%, stomatitis 8.3%, anorexia 2.8% and neutropenia 9.7%. There were no treatment-related deaths. The pharmacokinetics profiles of S-1 plus LV in Chinese patients were similar to those in Japanese patients. This 2-week schedule of S-1 plus LV showed good efficacy and better tolerability than the 4-week schedule. This therapy will be the base regimen for mCRC to be added by other cytotoxic or molecular-targeted drugs. The optimized treatment schedule for S-1 plus LV was 1 week on and 1 week off.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Neoplasias Colorretais/tratamento farmacológico
Leucovorina/administração & dosagem
Ácido Oxônico/administração & dosagem
Tegafur/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Anorexia/induzido quimicamente
Anorexia/epidemiologia
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
China
Diarreia/induzido quimicamente
Diarreia/epidemiologia
Esquema de Medicação
Combinação de Medicamentos
Feminino
Seres Humanos
Japão
Leucovorina/efeitos adversos
Leucovorina/farmacocinética
Masculino
Meia-Idade
Metástase Neoplásica
Neutropenia/induzido quimicamente
Neutropenia/epidemiologia
Ácido Oxônico/efeitos adversos
Ácido Oxônico/farmacocinética
Estomatite/induzido quimicamente
Estomatite/epidemiologia
Análise de Sobrevida
Tegafur/efeitos adversos
Tegafur/farmacocinética
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 150863-82-4 (S 1 (combination)); 1548R74NSZ (Tegafur); 5VT6420TIG (Oxonic Acid); Q573I9DVLP (Leucovorin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170802
[St] Status:MEDLINE
[do] DOI:10.1111/cas.13335


  10 / 5248 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28752564
[Au] Autor:Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
[Ad] Endereço:Olivia Newton-John Cancer Research Institute, Level 5, Olivia Newton-John Cancer Wellness & Research Centre, Austin Hospital, 145-163 Studley Rd, Heidelberg, Victoria, Australia, 3084.
[Ti] Título:Oral versus intravenous fluoropyrimidines for colorectal cancer.
[So] Source:Cochrane Database Syst Rev;7:CD008398, 2017 Jul 28.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Patients prefer oral to intravenous (IV) palliative chemotherapy, provided that oral therapy is not less effective. We compared the efficacy and safety of oral and IV fluoropyrimidines for treatment of colorectal cancer (CRC). OBJECTIVES: To compare the effects of oral and IV fluoropyrimidine chemotherapy in patients treated with curative or palliative intent for CRC. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 5), along with OVID MEDLINE, OVID Embase, and Web of Science databases, in June 2016. We also searched five clinical trials registers, several conference proceedings, and reference lists from study reports and systematic reviews. We contacted pharmaceutical companies to identify additional studies. SELECTION CRITERIA: We included randomised controlled trials (RCTs) comparing oral and IV fluoropyrimidine chemotherapy in patients treated with curative or palliative intent for CRC. DATA COLLECTION AND ANALYSIS: Three review authors extracted data and assessed risk of bias independently. We assessed the seven domains in the Cochrane 'Risk of bias' tool and three additional domains: schedules of outcome assessment and/or follow-up; use of intention-to-treat analysis; and baseline comparability of treatment arms. MAIN RESULTS: We included nine RCTs (total of 10,918 participants) that examined treatment with curative intent for CRC with neoadjuvant and/or adjuvant chemotherapy. We included 35 RCTs (total of 12,592 participants) that examined treatment with palliative intent for inoperable advanced or metastatic CRC with chemotherapy (31 first-line studies, two second-line studies, and two studies of first- or second-line chemotherapy). All studies included male and female participants, and no studies included participants younger than 18 years of age. Patients treated with curative intent for CRC with neoadjuvant and/or adjuvant chemotherapy • Disease-free survival (DFS): DFS did not differ between participants treated with oral versus IV fluoropyrimidines (hazard ratio (HR) 0.93, 95% confidence interval (CI) 0.87 to 1.00; seven studies, 8903 participants; moderate-quality evidence).• Overall survival (OS): OS did not differ between participants treated with oral versus IV fluoropyrimidines (HR 0.92, 95% CI 0.84 to 1.00; seven studies, 8902 participants analysed; high-quality evidence).• Grade ≥ 3 adverse events (AEs): Participants treated with oral fluoropyrimidines experienced less grade ≥ 3 neutropenia/granulocytopenia (odds ratio (OR) 0.14, 95% CI 0.11 to 0.16; seven studies, 8087 participants; moderate-quality evidence), stomatitis (OR 0.21, 95% CI 0.14 to 0.30; five studies, 4212 participants; low-quality evidence), and any grade ≥ 3 AEs (OR 0.82, 95% CI 0.74 to 0.90; five studies, 7741 participants; low-quality evidence). There was more grade ≥ 3 hand foot syndrome (OR 4.59, 95% CI 2.97 to 7.10; five studies, 5731 participants; low-quality evidence) in patients treated with oral fluoropyrimidines. There were no differences between participants treated with oral versus IV fluoropyrimidines in occurrence of grade ≥ 3 diarrhoea (OR 1.12, 95% CI 0.99 to 1.25; nine studies, 9551 participants; very low-quality evidence), febrile neutropenia (OR 0.59, 95% CI 0.18 to 1.90; four studies, 2925 participants; low-quality evidence), vomiting (OR 1.05, 95% CI 0.83 to 1.34; eight studies, 9385 participants; low-quality evidence), nausea (OR 1.21, 95% CI 0.97 to 1.51; seven studies, 9233 participants; low-quality evidence), mucositis (OR 0.64, 95% CI 0.25 to 1.62; four studies, 2233 participants; very low-quality evidence), and hyperbilirubinaemia (OR 1.67, 95% CI 0.52 to 5.38; three studies, 2757 participants; very low-quality evidence). Patients treated with palliative intent for inoperable advanced or metastatic CRC with chemotherapy • Progression-free survival (PFS): Overall, PFS was inferior in participants treated with oral versus IV fluoropyrimidines (HR 1.06, 95% CI 1.02 to 1.11; 23 studies, 9927 participants; moderate-quality evidence). Whilst PFS was worse in participants treated with oral compared with IV fluoropyrimidines when UFT/Ftorafur or eniluracil with oral 5-fluorouracil (5-FU) was used, PFS did not differ between individuals treated with oral versus IV fluoropyrimidines when capecitabine, doxifluridine, or S-1 was used.• OS: Overall, OS did not differ between participants treated with oral versus IV fluoropyrimidines (HR 1.02, 95% CI 0.99 to 1.05; 29 studies, 12,079 participants; high-quality evidence). OS was inferior in participants treated with oral versus IV fluoropyrimidines when eniluracil with oral 5-fluorouracil (5-FU) was used.• Time to progression (TTP): TTP was inferior in participants treated with oral versus IV fluoropyrimidines (HR 1.07, 95% CI 1.01 to 1.14; six studies, 1970 participants; moderate-quality evidence).• Objective response rate (ORR): ORR did not differ between participants treated with oral versus IV fluoropyrimidines (OR 0.98, 95% CI 0.90 to 1.06; 32 studies, 11,115 participants; moderate-quality evidence).• Grade ≥ 3 AEs: Participants treated with oral fluoropyrimidines experienced less grade ≥ 3 neutropenia/granulocytopenia (OR 0.17, 95% CI 0.15 to 0.18; 29 studies, 11,794 participants; low-quality evidence), febrile neutropenia (OR 0.27, 95% CI 0.21 to 0.36; 19 studies, 9407 participants; moderate-quality evidence), stomatitis (OR 0.26, 95% CI 0.20 to 0.33; 21 studies, 8718 participants; low-quality evidence), mucositis (OR 0.17, 95% CI 0.12 to 0.24; 12 studies, 4962 participants; low-quality evidence), and any grade ≥ 3 AEs (OR 0.83, 95% CI 0.74 to 0.94; 14 studies, 5436 participants; low-quality evidence). There was more grade ≥ 3 diarrhoea (OR 1.66, 95% CI 1.50 to 1.84; 30 studies, 11,997 participants; low-quality evidence) and hand foot syndrome (OR 3.92, 95% CI 2.84 to 5.43; 18 studies, 6481 participants; moderate-quality evidence) in the oral fluoropyrimidine arm. There were no differences between oral and IV fluoropyrimidine arms in terms of grade ≥ 3 vomiting (OR 1.18, 95% CI 1.00 to 1.40; 23 studies, 9528 participants; low-quality evidence), nausea (OR 1.16, 95% CI 0.99 to 1.36; 25 studies, 9796 participants; low-quality evidence), and hyperbilirubinaemia (OR 1.62, 95% CI 0.99 to 2.64; nine studies, 2699 participants; low-quality evidence). AUTHORS' CONCLUSIONS: Results of this review should provide confidence that treatment for CRC with most of the oral fluoropyrimidines commonly used in current clinical practice is similarly efficacious to treatment with IV fluoropyrimidines. Treatment with eniluracil with oral 5-FU was associated with inferior PFS and OS among participants treated with palliative intent for CRC, and eniluracil is no longer being developed. Oral and IV fluoropyrimidines have different patterns of side effects; future research may focus on determining the basis for these differences.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Neoplasias Colorretais/tratamento farmacológico
Pirimidinas/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Antineoplásicos/efeitos adversos
Camptotecina/administração & dosagem
Camptotecina/análogos & derivados
Capecitabina/administração & dosagem
Quimioterapia Adjuvante
Neoplasias Colorretais/mortalidade
Neoplasias Colorretais/patologia
Intervalo Livre de Doença
Feminino
Floxuridina/administração & dosagem
Fluoruracila/administração & dosagem
Seres Humanos
Injeções Intravenosas
Masculino
Terapia Neoadjuvante
Compostos Organoplatínicos/administração & dosagem
Cuidados Paliativos
Piridinas/administração & dosagem
Ensaios Clínicos Controlados Aleatórios como Assunto
Tegafur/administração & dosagem
Uracila/administração & dosagem
Uracila/análogos & derivados
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Organoplatinum Compounds); 0 (Pyridines); 0 (Pyrimidines); 0 (oxiplatin); 039LU44I5M (Floxuridine); 1548R74NSZ (Tegafur); 2E2W0W5XIU (eniluracil); 56HH86ZVCT (Uracil); 6804DJ8Z9U (Capecitabine); 7673326042 (irinotecan); U3P01618RT (Fluorouracil); V1JK16Y2JP (doxifluridine); XT3Z54Z28A (Camptothecin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170729
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD008398.pub2



página 1 de 525 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde